Drugs / SOK583A1
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05282004 | May → Sep 2022 | wet macular degeneration | Sandoz | Completed | No outcome recorded |
| Phase 3 | NCT05161806 | Mar → May 2022 | wet macular degeneration | Sandoz | Completed | No outcome recorded |
| Phase 3 | NCT04864834 | May 2021 → Jul 2022 | wet macular degeneration | Sandoz | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOK583A1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05282004 ↗ |
| Modality | Protein / enzyme biologic | “a Proposed Aflibercept Biosimilar Product” NCT05282004 ↗ |
| Route | Intravitreal | “Administered Intravitreally” NCT04864834 ↗ |